Table 1.

Distribution of insulin products in Bengaluru region, by insulin type, place of manufacture and marketing companies

a. Private-sector retail (N = 30) and hospital pharmacies (N = 5)
		Products Marketed by Indian companies (Biocon, Wockhardt, Lupin, Cadila, Nicholas Piramal, Ranbaxy)	Products Marketed by Non-Indian Companies (Novo Nordisk, Eli Lilly and Sanofi)
Place of Manufacture	INDIA	Total (N = 109) Human = 89.0% (n = 97) Analogue = 10.1% (n = 11) Porcine = 0.9% (n = 1)	Total (N = 159) Human = 81.1% (n = 129) Analogue = 18.2% (n = 29) Porcine = 0.6% (n = 1)
	OUTSIDE INDIA	Total (N = 0)	Total (N = 72) Human = 40.3% (n = 29) Analogue = 59.7% (n = 43)
b. Public-sector hospital pharmacies (n = 5)
		Products Marketed by Indian companies (Biocon, Lupin, Cadila Healthcare)	Products Marketed by Non-Indian Companies (Novo Nordisk, Eli Lilly and Sanofi)
Place of Manufacture	INDIA	Total (N = 11) Human = 81.8% (n = 9) Analogue = 18.2% (n = 2)	Total (N = 11) Human = 90.9% (n = 10) Analogue = 9.1% (n = 1)
	OUTSIDE INDIA	Total (N = 0)	Total (N = 6) Human = 33.3% (n = 2) Analogue = 66.7% (n = 4)

‘n’ indicates total number of products included in a given segment, irrespective of dosage, strength and delivery device